Shire Laboratories has filed patent infringement lawsuits in the U.S. District Court for the District of New Jersey and the Southern District of Florida against Andrx Pharmaceuticals (recently acquired by Watson Laboratories) for Infringement of the U.S. Patent Nos. 6,322,819 (the ‘819 patent) and 6,605,300 (the ‘300 patent). The lawsuits are result of Para IV certification by Andrx filed with USFDA seeking market approval for its abbreviated new drug application for generic versions of 5mg, 10mg, 15mg, 20mg, 25mg and 30mg Adderall XR before the expiration of the ‘819 and ‘300 patents in 2018.
No comments:
Post a Comment